Press release
Pulmonary Embolism Market Poised to Hit US$3.5 Billion by 2031, Driven by Rising Incidence and Advancements in Treatment at 8.1% CAGR
Pulmonary Embolism Market
The global pulmonary embolism (PE) market is experiencing robust growth, expected to surge from US$1.5 billion in 2024 to approximately US$3.5 billion by 2031, expanding at a CAGR of 8.1%. This growth is fueled by the increasing prevalence of risk factors such as cancer, obesity, smoking, and sedentary lifestyles, particularly among the aging population. Pulmonary embolism is a potentially fatal condition resulting from blood clots in the lungs and remains a critical area of focus in both diagnostics and treatment innovation.
Get a Sample PDF Brochure of the Report (Use Corporate Email ID for a Quick Response): https://www.persistencemarketresearch.com/samples/34496
The market's leading segment is medications, particularly anticoagulants, owing to their efficacy and minimal invasiveness. Hospitals dominate as the primary end-user due to their capacity to manage emergency cases and provide multidisciplinary care. Regionally, North America holds the largest market share, attributed to its advanced healthcare infrastructure, high per capita healthcare expenditure, and increased disease prevalence driven by aging demographics and lifestyle-related conditions.
✦ Key Highlights from the Report:
✦ The pulmonary embolism market is projected to grow at a CAGR of 8.1% from 2024 to 2031.
✦ The market is expected to reach a valuation of US$3.5 billion by 2031.
✦ Medications are the leading treatment type, particularly anticoagulants.
✦ CT pulmonary angiography (CTPA) remains the gold standard diagnostic tool.
✦ North America dominates the market due to its advanced medical infrastructure.
✦ Hospital pharmacies lead in PE medication distribution and management.
Market Segmentation 🔀
The pulmonary embolism market is segmented based on treatment type, diagnostic tools, end users, and distribution channels. Among treatment types, medications dominate due to their accessibility and efficacy in reducing clot formation and recurrence. These include blood thinners like heparin and direct oral anticoagulants (DOACs).
In diagnostics, CT pulmonary angiography (CTPA) is the most preferred tool because of its speed, accuracy, and detailed imaging capabilities. Other tools such as V/Q scans and D-dimer tests are also utilized based on patient profiles.
From an end-user perspective, hospitals are the primary adopters of PE treatments due to the urgent and intensive care required in many cases. They also offer specialized diagnostic imaging and surgical interventions. Hospital pharmacies dominate the distribution segment by providing immediate access to critical care medications, with retail pharmacies expected to gain traction as outpatient treatments and long-term therapies increase.
Regional Insights 🌍
North America leads the pulmonary embolism market with the highest revenue share, owing to a high disease burden, increased healthcare awareness, and widespread adoption of advanced treatment methods. The region benefits from the presence of top pharmaceutical companies, high healthcare spending, and well-established reimbursement systems.
Europe follows closely due to its strong regulatory framework, growing elderly population, and high prevalence of cancer and cardiovascular diseases. Asia Pacific is anticipated to witness the fastest growth during the forecast period. Factors contributing to this include increasing healthcare investments, improved diagnostic capabilities, and rising public awareness. Countries like India and China are showing considerable improvement in healthcare infrastructure and patient outreach programs.
📊 Market Drivers
The rise in cancer incidence globally is a significant driver for the pulmonary embolism market. Chemotherapy and cancer itself increase the risk of venous thromboembolism (VTE), including PE. According to WHO, cancer was responsible for approximately 10 million deaths in 2020, intensifying the need for advanced treatment protocols.
Growing investments in healthcare infrastructure, including imaging and minimally invasive treatment options, are enhancing diagnostic and therapeutic outcomes. Additionally, the increasing prevalence of lifestyle-related diseases and tobacco addiction, particularly among urban populations, is elevating PE risk factors, contributing to higher demand for treatment solutions.
🚫 Market Restraints
One of the major restraints hindering market growth is the lack of awareness among patients and some healthcare providers about PE symptoms and treatment options. Delayed diagnosis can lead to severe complications or fatalities, limiting the effectiveness of treatments.
High treatment costs also pose a challenge, especially in low- and middle-income regions. Advanced diagnostic procedures like CTPA and specialized medications are often expensive, putting pressure on both healthcare systems and patients.
✨ Market Opportunities
The market holds tremendous opportunities, particularly in R&D and innovation. Research surrounding the causes, diagnostics, and treatment of PE is expanding, with several novel therapies and medical devices in the pipeline.
Drug approvals and the launch of next-generation treatment devices, including catheter-based thrombolysis tools and AI-assisted diagnostic platforms, are likely to improve patient outcomes. The integration of telemedicine for follow-up and monitoring also presents new growth avenues, especially in remote and underserved regions.
Do You Have Any Query Or Specific Requirement? Request Customization of Report: https://www.persistencemarketresearch.com/request-customization//34496
Frequently Asked Questions (FAQs):
How Big is the Pulmonary Embolism Market?
What is the Projected Growth Rate of the Pulmonary Embolism Market?
Who are the Key Players in the Global Market for Pulmonary Embolism?
What is the Market Forecast for Pulmonary Embolism Treatment by 2031
Which Region is Estimated to Dominate the Pulmonary Embolism Industry through the Forecast Period?
Company Insights 💼
• Bayer AG
• Johnson & Johnson
• Boehringer Ingelheim
• Pfizer Inc.
• Bristol-Myers Squibb
• Amgen Inc.
• AbbVie Inc.
• Anthos Therapeutics
• Astellas Pharma Inc
.• argenx SE
• Daiichi Sankyo Co. Ltd.
• F. Hoffmann-La Roche Ltd.
• Eli Lilly and Co.
• Gilead Sciences Inc.
• Medtronic Plc
• Inari Medical Inc.
• Novartis AG
• Sanofi• Viatris Inc.
• Takeda Pharmaceutical Co. Ltd.
Recent Developments:
In May 2024, AngioDynamics announced that its AlphaVac device successfully demonstrated enhanced safety and efficacy in treating acute PE during clinical trials.
In May 2024, BMHRC successfully performed a catheter-directed thrombolysis (CDT) procedure on a PE patient, offering a promising less invasive treatment option.
Conclusion
The pulmonary embolism market is poised for significant expansion driven by a rising global disease burden, advancements in diagnostic and therapeutic technologies, and increasing healthcare investments. While challenges like high costs and lack of awareness persist, the growing focus on innovation and preventive care offers a robust platform for future growth. The increasing inclination toward minimally invasive procedures, personalized medicine, and AI-driven diagnostics ensures that the market will remain dynamic and opportunity-rich over the forecast period. With North America setting the pace, emerging markets in Asia-Pacific also show great promise for the future of pulmonary embolism management and treatment.
Persistence Market Research
G04 Golden Mile House, Clayponds Lane
Brentford, London, TW8 0GU UK
USA Phone: +1 646-878-6329
UK Phone: +44 203-837-5656
Email: sales@persistencemarketresearch.com
Web:
https://www.persistencemarketresearch.com
About Persistence Market Research:
At Persistence Market Research, we specialize in creating research studies that serve as strategic tools for driving business growth. Established as a proprietary firm in 2012, we have evolved into a registered company in England and Wales in 2023 under the name Persistence Research & Consultancy Services Ltd. With a solid foundation, we have completed over 3600 custom and syndicate market research projects, and delivered more than 2700 projects for other leading market research companies' clients.
Our approach combines traditional market research methods with modern tools to offer comprehensive research solutions. With a decade of experience, we pride ourselves on deriving actionable insights from data to help businesses stay ahead of the competition. Our client base spans multinational corporations, leading consulting firms, investment funds, and government departments. A significant portion of our sales comes from repeat clients, a testament to the value and trust we've built over the years.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Pulmonary Embolism Market Poised to Hit US$3.5 Billion by 2031, Driven by Rising Incidence and Advancements in Treatment at 8.1% CAGR here
News-ID: 4066877 • Views: …
More Releases from Persistence Market Research
Stadium Lighting Industry Forecasted to Grow Steadily, Driven by Transition from …
The global stadium lighting market is undergoing a transformative shift driven by rapid advancements in LED technology, energy efficiency mandates, and the growing popularity of smart, connected lighting systems. The transition from traditional metal halide lighting to LED-based stadium lighting is revolutionizing how sports arenas and outdoor venues are illuminated-offering longer lifespan, improved color rendering, and significantly lower maintenance costs.
Metal halide lights, which last around 6,000 hours, are increasingly being…
POS Machines Market Expected to Grow at a CAGR of 9.6% Through 2033
The global Point-of-Sale (POS) Machines Market is witnessing significant expansion as digital transactions continue to redefine modern commerce. As of 2022, the market size stood at US$ 18,221.3 million, and it is expected to reach US$ 49,365.2 million by 2033, growing at an impressive CAGR of 9.6% between 2023 and 2033. The increasing adoption of electronic payment systems, integration of advanced technologies like AI and cloud computing, and demand for…
3D Camera Market Projected to Reach USD 140.3 Billion by 2030
The global 3D camera market is witnessing an unprecedented surge, transforming how industries capture, process, and visualize images. Valued at US$ 21.0 billion in 2023, the market is projected to reach a staggering US$ 140.3 billion by 2030, growing at an exceptional CAGR of 30.1% during the forecast period. This exponential growth is primarily driven by the rising integration of 3D imaging in smartphones, virtual reality (VR), autonomous vehicles, and…
Parental Control Software Market Poised for Growth at an 11.1% CAGR Through 2030
The global parental control software market is projected to grow steadily, expanding from US$1.1 billion in 2023 to US$2.3 billion by 2030, registering a robust CAGR of 11.1%. This growth reflects the increasing digitalization of children's lives and the rising awareness among parents about online safety. The proliferation of smartphones, tablets, and internet-connected devices has created an urgent need for tools that allow guardians to monitor, filter, and restrict access…
More Releases for Pulmonary
Innovation In Pulmonary Drug Delivery Devices Industry Trends Gaining Momentum i …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Pulmonary Drug Delivery Devices Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
The market size for pulmonary drug delivery devices has experienced significant growth in the past few years. The market is projected to increase from $49.52 billion in 2024 to $52.8 billion in 2025,…
Chronic Pulmonary Aspergillosis Drugs Market - Revitalizing Lungs: Revolutionary …
Newark, New Castle, USA - new report, titled Chronic Pulmonary Aspergillosis Drugs Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Chronic Pulmonary Aspergillosis Drugs market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Chronic Pulmonary Aspergillosis Drugs market. The report offers…
Global Pulmonary Arterial Hypertension Market Size
According to a new market research report published by Global Market Estimates, the Global Pulmonary Arterial Hypertension Market is projected to grow at a CAGR of 5.2% from 2022 to 2027.
Congenital heart diseases and other ailments such as HIV infection, chronic liver disease (cirrhosis), and connective tissue disorders (scleroderma, lupus, and others) are fueling market expansion.
Browse 153 Market Data Tables and 113 Figures spread through 185 Pages and in-depth TOC…
New Study: Pulmonary Drugs Market Report
The pulmonary drugs market is expected to witness unprecedented growth in the near future, thanks to large number of approvals from the FDA. The FDA approved a large number of pulmonary drugs for major illnesses like small-cell lung cancer, tuberculosis, and pneumonia over the past few years. Additionally, newly approved drugs also treat newly found diseases like obstructive sleep apnea. These approvals are in line with the recent trend of…
Pulmonary Drugs Market Forecast till 2025
Pulmonary Drugs Market – Boon for Diseased Lungs
Pulmonary drugs can treat wide range of conditions, which are included within the ambit of pulmonary diseases such as pneumonia, allergic rhinitis, pulmonary hypertension, and others. . Pulmonary drugs provide medications for all types of pulmonary diseases, which is expected to fuel market growth in near future. The World Health Organization (WHO) states that most respiratory diseases are preventable and can be treated…
Pulmonary Drug Delivery Devices Market: Demand for Pulmonary Drug Delivery Devic …
This report on pulmonary drug delivery devices studies the current as well as future prospects of the market globally. The stakeholders of this report include companies and intermediaries engaged in the manufacture and commercialization of various pulmonary/respiratory drugs and/or drug-device combinations as well as new entrants planning to enter this market.
This report comprises an elaborate executive summary along with a market snapshot providing overall information of various segments and sub-segments…
